report_lead_image_with_gradient.png
Q2 2024

PitchBook Analyst Note: Takeaways From the 2024 Healthcare Capital Markets & Innovation Summit

Download this Report
To download this report, please complete the form below

Antitrust looms large over PE in healthcare
PE firms are watching with bated breath as California deliberates on legislation to further strengthen regulators’ remit to challenge PE bets in healthcare. At the 2024 Healthcare Capital Markets & Innovation Summit Conference, regulatory scrutiny was the talk of the town: Headline risk and state-level review requirements pose the most pressing threat, emboldened by the Federal Trade Commission’s more proactive approach.

But there are positive tailwinds for investors too, shared in our latest analyst note. After the successful IPO of healthcare payments company Waystar, the promise of an exit for large healthcare IT platform specialists feels much more real. On the deals side, there is momentum brewing in pharma services.


Table of contents
Key takeaways 1
Introduction 2
Deal outlook 2
Regulatory risks 3
Quick takes 4